Werewolf Therapeutics Inc (HOWL) Stock Price, Quote & News

Company Profile

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activa...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 952 0555

Website: werewolftx.com

Address:

200 Talcott Ave, 2nd Floor, Watertown, United States

the_real_Joker Oct. 24 at 2:10 PM

$HOWL Yea, I missed selling that thing too; I could have bought it back now. However, I'm still well in the black. But it takes more patience than $IXHL and $LEXX in my long BIO Portfolio. It'll be fine. I still believe in the products of these. ... back in in $MIRA & $PSTV...

1 · Reply

zawojak Oct. 23 at 9:48 PM

$HOWL Now Zacks #1

0 · Reply

hbkstockislife Oct. 20 at 11:21 AM

$HOWL green market red red market red ..scam

0 · Reply

trading_momentum_x Oct. 19 at 3:46 AM

$HOWL looks like it is currently stuck in chop and doesn't have too much momentum at the moment. Key resistance for this one will be at that 2.5 level. Key support at that 1.5 level. Bearish for now

1 · Reply

Lovelylatta Oct. 14 at 10:24 PM

$HOWL I really like this animal.

0 · Reply

zawojak Oct. 13 at 1:47 PM

$HOWL omg tanking on no news, thats very bad.

0 · Reply

Believer1975 Oct. 10 at 11:52 PM

$HOWL for right now, it's low because the market is RED

0 · Reply

Dukemandu Oct. 10 at 2:15 PM

$HOWL You guys having fun yet? This stock is the biggest piece of 💩 I have ever watched. Does everyone remember when BOA said this would be 10 bucks by now last year? They should be sued. I see absolutely no reason why this stock should be at that price, even though the rest of the market is screaming.

3 · Reply

zawojak Oct. 10 at 6:38 AM

$HOWL why so many institutions dumping it jezzzz????

0 · Reply

LabPsycho Oct. 9 at 11:55 PM

$HOWL A week ago when this was around $2.20 I posted the below message...when there is that phantom crash like HOWL did (then briefly recovered) in my observations, the stock almost always retraces below that prior low. I think the run is done on HOWL for a while.

2 · Reply

Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer

Oct 3, 2025, 9:00 AM EDT - 22 days ago

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Sep 2, 2025, 8:00 AM EDT - 7 weeks ago

Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 7:00 AM EDT - 2 months ago

Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 9, 2025, 8:00 AM EDT - 3 months ago

Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit

Jun 12, 2025, 8:00 AM EDT - 4 months ago

Werewolf Therapeutics to Participate in the BIO International Convention

May 29, 2025, 8:00 AM EDT - 5 months ago

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

May 20, 2025, 4:01 PM EDT - 5 months ago

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124

May 13, 2025, 8:00 AM EDT - 5 months ago

Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit

May 8, 2025, 7:00 AM EDT - 6 months ago

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 8:05 AM EDT - 6 months ago

Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

May 5, 2025, 8:00 AM EDT - 6 months ago

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

Apr 17, 2025, 8:00 AM EDT - 6 months ago

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

Mar 31, 2025, 8:00 AM EDT - 7 months ago

Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 11, 2025, 7:00 AM EDT - 8 months ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 4, 2025, 8:00 AM EST - 8 months ago

Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference

Feb 24, 2025, 7:30 AM EST - 8 months ago

Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

Jan 13, 2025, 8:00 AM EST - 10 months ago

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

Nov 20, 2024, 8:00 AM EST - 1 year ago

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 7, 2024, 9:02 AM EST - 1 year ago

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Aug 8, 2024, 7:05 AM EDT - 1 year ago

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 1, 2024, 10:04 AM EDT - 1 year ago

Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Jun 1, 2024, 9:00 AM EDT - 1 year ago

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

May 30, 2024, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference

May 23, 2024, 5:00 PM EDT - 1 year ago

Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting

May 3, 2024, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 24, 2024, 10:05 AM EDT - 1 year ago

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

Apr 5, 2024, 4:30 PM EDT - 1 year ago

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

Apr 4, 2024, 4:57 PM EDT - 1 year ago

Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space

Apr 4, 2024, 4:30 PM EDT - 1 year ago

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

Mar 7, 2024, 7:00 AM EST - 1 year ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 6, 2024, 8:00 AM EST - 1 year ago

Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

Mar 5, 2024, 4:30 PM EST - 1 year ago

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

Jan 8, 2024, 7:00 AM EST - 1 year ago

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

Jan 4, 2024, 4:05 PM EST - 1 year ago

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

Dec 28, 2023, 7:09 PM EST - 1 year ago

Werewolf Therapeutics: Still In The Race To Develop Next Generation Cytokines

Nov 22, 2023, 7:00 AM EST - 2 years ago

Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

Nov 14, 2023, 4:25 PM EST - 2 years ago

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 6, 2023, 5:14 PM EST - 2 years ago

Werewolf Therapeutics: Possibly A Transformative IL-2, But Still Early Days

Nov 3, 2023, 7:00 AM EDT - 2 years ago

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Oct 31, 2023, 9:00 AM EDT - 2 years ago

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 27, 2023, 9:00 AM EDT - 2 years ago

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 11, 2023, 4:05 PM EDT - 2 years ago

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

Aug 25, 2023, 4:48 PM EDT - 2 years ago

Werewolf: Q4 2023 Data Readout And Enhancement Of Validated Targets

Aug 10, 2023, 7:10 AM EDT - 2 years ago

Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Jun 1, 2023, 7:00 AM EDT - 2 years ago

Werewolf Therapeutics to Present at the Jefferies Healthcare Conference

May 11, 2023, 7:00 AM EDT - 2 years ago

Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

the_real_Joker Oct. 24 at 2:10 PM

1 · Reply

zawojak Oct. 23 at 9:48 PM

$HOWL Now Zacks #1

0 · Reply

hbkstockislife Oct. 20 at 11:21 AM

$HOWL green market red red market red ..scam

0 · Reply

trading_momentum_x Oct. 19 at 3:46 AM

$HOWL looks like it is currently stuck in chop and doesn't have too much momentum at the moment. Key resistance for this one will be at that 2.5 level. Key support at that 1.5 level. Bearish for now

1 · Reply

Lovelylatta Oct. 14 at 10:24 PM

$HOWL I really like this animal.

0 · Reply

zawojak Oct. 13 at 1:47 PM

$HOWL omg tanking on no news, thats very bad.

0 · Reply

Believer1975 Oct. 10 at 11:52 PM

$HOWL for right now, it's low because the market is RED

0 · Reply

Dukemandu Oct. 10 at 2:15 PM

3 · Reply

zawojak Oct. 10 at 6:38 AM

$HOWL why so many institutions dumping it jezzzz????

0 · Reply

LabPsycho Oct. 9 at 11:55 PM

2 · Reply

elmono Oct. 9 at 10:56 PM

$HOWL some MOFO shorters collective decided to short this: reason why it fell….company has to step up its game…fast

0 · Reply

_CircuitBreaker Oct. 9 at 9:47 PM

Keep a close watch on CMCT! $HOWL $CHPT $GIS $LPTX |

0 · Reply

Manonfire8 Oct. 9 at 9:13 PM

$GALT this may be of interest to the fam here, $HOWL sub 2 dollar play double digit price target and just received Fast Track Designation from the FDA today on their drug WTX-124

0 · Reply

zawojak Oct. 9 at 7:32 PM

$HOWL I am in with 1000 shares, you will hate me.

0 · Reply

ScubaTrading Oct. 8 at 10:52 PM

$HOWL nah…

0 · Reply

elmono Oct. 8 at 5:53 PM

$HOWL this ticker pisses me off. Bio’s are rocking, on top of that they bring excellent news…scam nano caps exploding everywhere….and we are….down 🤷‍♂️. That is why I sincerely hate biotech as a sector. The manipulation both ways is unprecedented to the point that it is one big casino instead of a serious market place 😂😂😂😂…..WTF

0 · Reply

jacksparo Oct. 8 at 4:46 PM

$HOWL Made a great swing from my last Sunday email here! Successfully completed ✅! Kept some for further hold ✅!

1 · Reply

johnjaha Oct. 8 at 4:36 PM

$HOWL

0 · Reply

bet_on_biotechs Oct. 8 at 4:32 PM

$HOWL I wonder if there are still a few idiots out there who'll sell their shares at this price after the positive news? It's hard to believe what the Crooks are up to. :-))))

1 · Reply

Lara50 Oct. 8 at 4:28 PM

$HOWL massive dilution of howl stock. stock price will continue to go down until a new pivotal bottom is found. this is a shortable stock, as there is no buying resistance whatsoever. short away

0 · Reply

SP_Win Oct. 8 at 1:41 PM

$HOWL

0 · Reply

johnjaha Oct. 8 at 12:56 PM

$HOWL

0 · Reply

Market Cap	80.94M
Revenue (ttm)	1.89M
Net Income (ttm)	-70.52M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,731.22%
Debt to Equity Ratio	0.60

Volume	1,065,100
Avg Vol	838,114
Day's Range	N/A - N/A
Shares Out	45.73M
Stochastic %K	80%
Beta	0.76
Analysts	Strong Sell
Price Target	$6.83